ArticleReproductive sciences (Thousand Oaks, Calif.)2014
Injectable Clostridium histolyticum collagenase as a potential treatment for uterine fibroids.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 41 citations in OpenAlex.
- Assessing the Impact of Collagenase Clostridium histolyticum Injection on Biomechanical Properties of Uterine Fibroids and Adjacent Myometrial Tissue.Reproductive sciences (Thousand Oaks, Calif.) · 2026Article
- Mechanical Stiffness Influences the Response of Human Uterine Fibroid Cells to Hormonal Treatments.Reproductive sciences (Thousand Oaks, Calif.) · 2026Article
- Detecting metabolic signatures in endometrial cancer: potential applications of Raman spectroscopy.Future oncology (London, England) · 2025Review
- Advancements and Emerging Therapies in the Medical Management of Uterine Fibroids: A Comprehensive Scoping Review.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Evidence-Based Approach for Secondary Prevention of Uterine Fibroids (The ESCAPE Approach).International journal of molecular sciences · 2023Review
- Prevention of Uterine Fibroids: molecular mechanisms and potential clinical application.Journal of endometriosis and uterine disorders · 2023Article
- The biotechnological potential of proteases from hematophagous arthropod vectors.Frontiers in cellular and infection microbiology · 2023Article
- Short Chain Fatty Acid Metabolism in Relation to Gut Microbiota and Genetic Variability.Nutrients · 2022Review
- Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment.Endocrine reviews · 2022Review
- Using rheology to quantify the effects of localized collagenase treatments on uterine fibroid digestion.Acta biomaterialia · 2021Article
- Extracellular matrix and Hippo signaling as therapeutic targets of antifibrotic compounds for uterine fibroids.Clinical and translational medicine · 2021Article
- Summary of the Proceedings of the Basic Science of Uterine Fibroids Meeting: New Developments February 28, 2020.F&S science · 2021Article
- The Evolving Role of Natural Compounds in the Medical Treatment of Uterine Fibroids.Journal of clinical medicine · 2020Review
- Assessment of corneal substrate biomechanics and its effect on epithelial stem cell maintenance and differentiation.Nature communications · 2019Article
- Article
- Recent scientific advances in leiomyoma (uterine fibroids) research facilitates better understanding and management.F1000Research · 2015Review
- Dynamic reciprocity between cells and their microenvironment in reproduction.Biology of reproduction · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purified Clostridium histolyticum collagenase (CHC), an Food and Drug Administration-approved drug that does not affect nerves or blood vessels, was assessed as a potential treatment for fibroids in this proof-of-principle study. Fibroids (1-4 cm, capsules intact) and myometrial specimens from 5 patients were injected posthysterectomy with CHC or vehicle containing methylene blue and incubated for 24 hours. Percentage of collagen-stained area was estimated using Masson-Trichrome-stained slides. Collagen fibers were observed with picrosirius staining. Tissue stiffness was objectively measured by rheometry (complex shear modulus [Pa]). Injected materials spread within and beyond fibroids as visualized by methylene blue. Of the 8 treated fibroids, 7 were softened and some contained liquefied centers. Relative percentage of collagen-stained area (mean ± standard deviation) in treated fibroids (38 ± 12%; n = 7) was less than that in control fibroids (66 ± 17%; n = 5). Treated myometrium (40 ± 30% collagen; n = 3) was similar to control myometrium (53 ± 8%; n = 2). Picrosirius staining demonstrated loss of collagen fibers in treated fibroids. Treated fibroids were less stiff (3630 ± 2410 Pa; n = 4) than controls (5930 ± 830 Pa; n = 4). Treated and control myometrium had similar stiffness (2149 ± 927 Pa; n = 3 and 3314 ± 494 Pa; n = 2, respectively) and were never liquefied. In conclusion, injections of CHC into encapsulated fibroids are feasible and effective. Heterogeneity of collagen types and quantities within individual fibroids may contribute to varied responses and need additional investigation. Further study of collateral effects on myometrium is indicated. Injected CHC has potential for treatment of fibroids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.